12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells

      research-article
      a , b , c , a , c , a , c , d , b , b , a , b , b , b , b , b , e , e , f , g , g , h , i , f , j , j , a , k , b , a , 1
      Proceedings of the National Academy of Sciences of the United States of America
      National Academy of Sciences
      cardiac peptide, cancer metastasis, vascular endothelial cell, inflammation, surgery

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Postoperative cancer recurrence is a major problem following curative cancer surgery. Perioperative systemic inflammation induces the adhesion of circulating tumor cells released from the primary tumor to the vascular endothelium of distant organs, which is the first step in hematogenous metastasis. We have previously reported that administration of atrial natriuretic peptide (ANP) during the perioperative period reduces inflammatory response and has a prophylactic effect on postoperative cardiopulmonary complications in lung cancer surgery. Here, we demonstrate that cancer recurrence after lung cancer surgery was significantly lower in ANP-treated patients than in control patients (surgery alone). We show that ANP prevents cancer metastasis by suppressing the inflammatory reaction of endothelial cells, thereby inhibiting cancer cell adhesion to vascular endothelial cells.

          Abstract

          Most patients suffering from cancer die of metastatic disease. Surgical removal of solid tumors is performed as an initial attempt to cure patients; however, surgery is often accompanied with trauma, which can promote early recurrence by provoking detachment of tumor cells into the blood stream or inducing systemic inflammation or both. We have previously reported that administration of atrial natriuretic peptide (ANP) during the perioperative period reduces inflammatory response and has a prophylactic effect on postoperative cardiopulmonary complications in lung cancer surgery. Here we demonstrate that cancer recurrence after curative surgery was significantly lower in ANP-treated patients than in control patients (surgery alone). ANP is known to bind specifically to NPR1 [also called guanylyl cyclase-A (GC-A) receptor]. In mouse models, we found that metastasis of GC-A–nonexpressing tumor cells (i.e., B16 mouse melanoma cells) to the lung was increased in vascular endothelium-specific GC-A knockout mice and decreased in vascular endothelium-specific GC-A transgenic mice compared with control mice. We examined the effect of ANP on tumor metastasis in mice treated with lipopolysaccharide, which mimics systemic inflammation induced by surgical stress. ANP inhibited the adhesion of cancer cells to pulmonary arterial and micro-vascular endothelial cells by suppressing the E-selectin expression that is promoted by inflammation. These results suggest that ANP prevents cancer metastasis by inhibiting the adhesion of tumor cells to inflamed endothelial cells.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

          The three principal studies dedicated to the natural history of peritoneal carcinomatosis (PC) from colorectal cancer consistently showed median survival ranging between 6 and 8 months. New approaches combining cytoreductive surgery and perioperative intraperitoneal chemotherapy suggest improved survival. A retrospective multicenter study was performed to evaluate the international experience with this combined treatment and to identify the principal prognostic indicators. All patients had cytoreductive surgery and perioperative intraperitoneal chemotherapy (intraperitoneal chemohyperthermia and/or immediate postoperative intraperitoneal chemotherapy). PC from appendiceal origin was excluded. The study included 506 patients from 28 institutions operated between May 1987 and December 2002. Their median age was 51 years. The median follow-up was 53 months. The morbidity and mortality rates were 22.9% and 4%, respectively. The overall median survival was 19.2 months. Patients in whom cytoreductive surgery was complete had a median survival of 32.4 months, compared with 8.4 months for patients in whom complete cytoreductive surgery was not possible (P <.001). Positive independent prognostic indicators by multivariate analysis were complete cytoreduction, treatment by a second procedure, limited extent of PC, age less than 65 years, and use of adjuvant chemotherapy. The use of neoadjuvant chemotherapy, lymph node involvement, presence of liver metastasis, and poor histologic differentiation were negative independent prognostic indicators. The therapeutic approach combining cytoreductive surgery with perioperative intraperitoneal chemotherapy achieved long-term survival in a selected group of patients with PC from colorectal origin with acceptable morbidity and mortality. The complete cytoreductive surgery was the most important prognostic indicator.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

            Rare circulating tumor cells (CTCs) are present in the blood of patients with metastatic epithelial cancers but have been difficult to measure routinely. We report a quantitative automated imaging system for analysis of prostate CTCs, taking advantage of prostate-specific antigen (PSA), a unique prostate tumor-associated marker. The specificity of PSA staining enabled optimization of criteria for baseline image intensity, morphometric measurements, and integration of multiple signals in a three-dimensional microfluidic device. In a pilot analysis, we detected CTCs in prostate cancer patients with localized disease, before surgical tumor removal in 8 of 19 (42%) patients (range, 38 to 222 CTCs per milliliter). For 6 of the 8 patients with preoperative CTCs, a precipitous postoperative decline (<24 hours) suggests a short half-life for CTCs in the blood circulation. Other patients had persistent CTCs for up to 3 months after prostate removal, suggesting early but transient disseminated tumor deposits. In patients with metastatic prostate cancer, CTCs were detected in 23 of 36 (64%) cases (range, 14 to 5000 CTCs per milliliter). In previously untreated patients followed longitudinally, the numbers of CTCs declined after the initiation of effective therapy. The prostate cancer-specific TMPRSS2-ERG fusion was detectable in RNA extracted from CTCs from 9 of 20 (45%) patients with metastatic disease, and dual staining of captured CTCs for PSA and the cell division marker Ki67 indicated a broad range for the proportion of proliferating cells among CTCs. This method for analysis of CTCs will facilitate the application of noninvasive tumor sampling to direct targeted therapies in advanced prostate cancer and warrants the initiation of long-term clinical studies to test the importance of CTCs in invasive localized disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targeting selectins and selectin ligands in inflammation and cancer.

              Inflammation and cancer metastasis are associated with extravasation of leukocytes or tumor cells from blood into tissue. Such movement is believed to follow a coordinated and sequential molecular cascade initiated, in part, by the three members of the selectin family of carbohydrate-binding proteins: E-selectin (CD62E), L-selectin (CD62L) and P-selectin (CD62P). E-selectin is particularly noteworthy in disease by virtue of its expression on activated endothelium and on bone-skin microvascular linings and for its role in cell rolling, cell signaling and chemotaxis. E-selectin, along with L- or P-selectin, mediates cell tethering and rolling interactions through the recognition of sialo-fucosylated Lewis carbohydrates expressed on structurally diverse protein-lipid ligands on circulating leukocytes or tumor cells. Major advances in understanding the role of E-selectin in inflammation and cancer have been advanced by experiments assaying E-selectin-mediated rolling of leukocytes and tumor cells under hydrodynamic shear flow, by clinical models of E-selectin-dependent inflammation, by mice deficient in E-selectin and by mice deficient in glycosyltransferases that regulate the binding activity of E-selectin ligands. Here, the authors elaborate on how E-selectin and its ligands may facilitate leukocyte or tumor cell recruitment in inflammatory and metastatic settings. Antagonists that target cellular interactions with E-selectin and other members of the selectin family, including neutralizing monoclonal antibodies, competitive ligand inhibitors or metabolic carbohydrate mimetics, exemplify a growing arsenal of potentially effective therapeutics in controlling inflammation and the metastatic behavior of cancer.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                31 March 2015
                16 March 2015
                16 March 2015
                : 112
                : 13
                : 4086-4091
                Affiliations
                [1] aDepartment of Biochemistry,
                [2] cDepartment of Regenerative Medicine and Tissue Engineering,
                [3] hDepartment of Molecular Biology, and
                [4] kJST-CREST/Department of Cell Biology, National Cerebral and Cardiovascular Center Research Institute , Suita-city, Osaka 565-8565, Japan;
                [5] bDepartment of General Thoracic Surgery and
                [6] jDepartment of Mathematical Health Science, Osaka University Graduate School of Medicine , Suita-city, Osaka, 565-0871, Japan;
                [7] dDepartment of Endocrinology and Metabolism, National Cerebral and Cardiovascular Center Hospital , Suita-city, Osaka 565-8565, Japan;
                [8] eDepartment of General Thoracic Surgery, National Hospital Organization Toneyama Hospital , Toyonaka-city, Osaka, 560-8552, Japan;
                [9] fDepartment of Signal Transduction, Research Institute for Microbial Diseases , Suita-city, Osaka 565-0871, Japan;
                [10] gLaboratory for Animal Resources and Genetic Engineering, RIKEN Center for Developmental Biology , Kobe-city, Hyogo 650-0047, Japan; and
                [11] iDrug Research Section II, Fukushima Research Laboratories, TOA EIYO Ltd. , Fukushima-city, Fukushima 960-0280, Japan
                Author notes
                1To whom correspondence should be addressed. Email: kangawa@ 123456ri.ncvc.go.jp .

                Edited * by Masashi Yanagisawa, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 18, 2015 (received for review September 7, 2014)

                Author contributions: T. Nojiri, H.H., T.T., N.T., M. Miyazato, N.M., M.O., and K.K. designed research; T. Nojiri, H.H., T.T., K.M., S.I., K.O., I.K., Y.S., M.I., T.K., N.S., M. Minami, T. Nakagiri, S.F., Y.T., H.M., H. Kidoya, and N.M. performed research; T. Nojiri, H. Kiyonari, G.S., and Y.A. contributed new reagents/analytic tools; T. Nojiri, T.H., M.H., and Y.O. analyzed data; and T. Nojiri, N.M., and K.K. wrote the paper.

                Article
                201417273
                10.1073/pnas.1417273112
                4386325
                25775533
                7a0c7520-8c28-408f-8e0e-7b737d004fe8

                Freely available online through the PNAS open access option.

                History
                Page count
                Pages: 6
                Categories
                Biological Sciences
                Medical Sciences

                cardiac peptide,cancer metastasis,vascular endothelial cell,inflammation,surgery

                Comments

                Comment on this article